» Articles » PMID: 36203014

Precise DNA Cleavage Using CRISPR-SpRYgests

Abstract

Methods for in vitro DNA cleavage and molecular cloning remain unable to precisely cleave DNA directly adjacent to bases of interest. Restriction enzymes (REs) must bind specific motifs, whereas wild-type CRISPR-Cas9 or CRISPR-Cas12 nucleases require protospacer adjacent motifs (PAMs). Here we explore the utility of our previously reported near-PAMless SpCas9 variant, named SpRY, to serve as a universal DNA cleavage tool for various cloning applications. By performing SpRY DNA digests (SpRYgests) using more than 130 guide RNAs (gRNAs) sampling a wide diversity of PAMs, we discovered that SpRY is PAMless in vitro and can cleave DNA at practically any sequence, including sites refractory to cleavage with wild-type SpCas9. We illustrate the versatility and effectiveness of SpRYgests to improve the precision of several cloning workflows, including those not possible with REs or canonical CRISPR nucleases. We also optimize a rapid and simple one-pot gRNA synthesis protocol to streamline SpRYgest implementation. Together, SpRYgests can improve various DNA engineering applications that benefit from precise DNA breaks.

Citing Articles

CRISPR/Cas9-mediated mutation provides a new insight into resveratrol biosynthesis by causing a metabolic pathway shift from flavonoids to stilbenoids in cells.

Lai G, Fu P, He L, Che J, Wang Q, Lai P Hortic Res. 2025; 12(1):uhae268.

PMID: 39802734 PMC: 11718387. DOI: 10.1093/hr/uhae268.


Leveraging plant-derived nanovesicles for advanced nucleic acid-based gene therapy.

Chai M, Gao B, Wang S, Zhang L, Pei X, Yue B Theranostics. 2025; 15(1):324-339.

PMID: 39744221 PMC: 11667239. DOI: 10.7150/thno.104507.


One-for-all gene inactivation via PAM-independent base editing in bacteria.

Li X, Wei Y, Wang S, Wang S, Xia P J Biol Chem. 2024; 301(1):108113.

PMID: 39706269 PMC: 11782819. DOI: 10.1016/j.jbc.2024.108113.


High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease.

Bzhilyanskaya V, Ma L, Liu S, Fox L, Whittaker M, Meis R Sci Transl Med. 2024; 16(769):eadj6779.

PMID: 39413163 PMC: 11753194. DOI: 10.1126/scitranslmed.adj6779.


Strategies for improving the genome-editing efficiency of class 2 CRISPR/Cas system.

Wang L, Han H Heliyon. 2024; 10(19):e38588.

PMID: 39397905 PMC: 11471210. DOI: 10.1016/j.heliyon.2024.e38588.


References
1.
Loenen W, Dryden D, Raleigh E, Wilson G, Murray N . Highlights of the DNA cutters: a short history of the restriction enzymes. Nucleic Acids Res. 2013; 42(1):3-19. PMC: 3874209. DOI: 10.1093/nar/gkt990. View

2.
Gibson D, Young L, Chuang R, Venter J, Hutchison 3rd C, Smith H . Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009; 6(5):343-5. DOI: 10.1038/nmeth.1318. View

3.
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna J, Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337(6096):816-21. PMC: 6286148. DOI: 10.1126/science.1225829. View

4.
Collias D, Beisel C . CRISPR technologies and the search for the PAM-free nuclease. Nat Commun. 2021; 12(1):555. PMC: 7822910. DOI: 10.1038/s41467-020-20633-y. View

5.
Wang J, Wang A, Li K, Wang B, Jin S, Reiser M . CRISPR/Cas9 nuclease cleavage combined with Gibson assembly for seamless cloning. Biotechniques. 2015; 58(4):161-70. DOI: 10.2144/000114261. View